Type I insulin-like growth factor (IGF) receptor (IGF1R) inhibitors are new cancer therapies. Pitts and colleagues used in vitro data to "train" a predictive biomarker for an IGF1R tyrosine kinase inhibitor. Given the complexity of IGF signaling, additional layers of biomarker analysis will likely be needed to develop predictive factors.
Yee, D. (2010, June 15). How to train your biomarker. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-10-0873